Results: Eurofins Scientific SE Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 27
French (CAC) Life Sciences Industry Analysis
UpdatedJul 27, 2024
DataAggregated Company Financials
Companies3
- 7D15.4%
- 3M-12.6%
- 1Y-31.0%
- YTD-23.8%
Over the last 7 days, the Life Sciences industry has dropped 1.6%, driven by Sartorius Stedim Biotech declining 7.9%. Overall the industry is down 34% in 12 months. Earnings are forecast to grow by 25% annually.
Industry Valuation and Performance
Has the French Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 27 Jul 2024 | €27.3b | €9.5b | €503.0m | 31.5x | 54.2x | 2.9x |
| Mon, 24 Jun 2024 | €25.6b | €9.3b | €518.8m | 39.7x | 49.3x | 2.8x |
| Wed, 22 May 2024 | €30.2b | €9.3b | €522.7m | 43.7x | 57.8x | 3.3x |
| Fri, 19 Apr 2024 | €32.1b | €9.3b | €522.7m | 45x | 61.3x | 3.5x |
| Sun, 17 Mar 2024 | €37.4b | €9.3b | €577.7m | 42x | 64.8x | 4x |
| Tue, 13 Feb 2024 | €32.9b | €9.5b | €885.8m | 25.2x | 37.2x | 3.5x |
| Thu, 11 Jan 2024 | €33.0b | €9.5b | €885.8m | 26.7x | 37.3x | 3.5x |
| Sat, 09 Dec 2023 | €29.6b | €9.5b | €885.8m | 25.6x | 33.4x | 3.1x |
| Mon, 06 Nov 2023 | €27.3b | €9.5b | €885.8m | 24x | 30.9x | 2.9x |
| Wed, 04 Oct 2023 | €30.9b | €9.7b | €1.1b | 24.2x | 29.1x | 3.2x |
| Fri, 01 Sep 2023 | €35.3b | €9.7b | €1.1b | 26.5x | 33.2x | 3.6x |
| Sun, 30 Jul 2023 | €38.2b | €9.7b | €1.1b | 29x | 36x | 3.9x |
| Tue, 27 Jun 2023 | €31.8b | €10.1b | €1.3b | 18.6x | 24.3x | 3.1x |
| Thu, 25 May 2023 | €34.6b | €10.1b | €1.3b | 20.5x | 26.4x | 3.4x |
| Sat, 22 Apr 2023 | €35.3b | €10.1b | €1.3b | 20.3x | 27x | 3.5x |
| Mon, 20 Mar 2023 | €39.8b | €10.3b | €1.5b | 20.4x | 27.1x | 3.9x |
| Wed, 15 Feb 2023 | €44.7b | €10.3b | €1.3b | 20.2x | 33.5x | 4.3x |
| Fri, 13 Jan 2023 | €41.8b | €10.3b | €1.3b | 19.4x | 31.3x | 4.1x |
| Sun, 11 Dec 2022 | €41.9b | €10.5b | €1.3b | 19.8x | 32.4x | 4x |
| Tue, 08 Nov 2022 | €41.5b | €10.5b | €1.3b | 19.8x | 32.1x | 4x |
| Thu, 06 Oct 2022 | €44.3b | €10.3b | €1.2b | 19.1x | 35.8x | 4.3x |
| Sat, 03 Sep 2022 | €47.3b | €10.3b | €1.2b | 20.2x | 38.2x | 4.6x |
| Mon, 01 Aug 2022 | €50.8b | €10.3b | €1.2b | 22.8x | 41x | 4.9x |
| Wed, 29 Jun 2022 | €43.3b | €10.0b | €1.3b | 20.1x | 33.9x | 4.3x |
| Fri, 27 May 2022 | €44.9b | €10.0b | €1.3b | 21.8x | 35.3x | 4.5x |
| Sun, 24 Apr 2022 | €46.6b | €10.0b | €1.3b | 22.9x | 36.6x | 4.6x |
| Tue, 22 Mar 2022 | €51.4b | €9.8b | €1.1b | 23.8x | 45.5x | 5.2x |
| Thu, 17 Feb 2022 | €49.5b | €9.3b | €1.3b | 20x | 36.9x | 5.4x |
| Sat, 15 Jan 2022 | €51.8b | €9.3b | €1.3b | 21.5x | 38.6x | 5.6x |
| Mon, 13 Dec 2021 | €65.0b | €9.3b | €1.3b | 25.1x | 48.5x | 7x |
| Wed, 10 Nov 2021 | €63.1b | €9.3b | €1.3b | 23.8x | 47.1x | 6.8x |
| Fri, 08 Oct 2021 | €61.4b | €9.0b | €1.3b | 24.9x | 47.6x | 6.8x |
| Sun, 05 Sep 2021 | €72.7b | €9.0b | €1.3b | 28.5x | 56.3x | 8.1x |
| Tue, 03 Aug 2021 | €64.4b | €9.0b | €1.3b | 23.7x | 49.9x | 7.1x |
Price to Earnings Ratio
49.9x
Current Industry PE
- There are only 3 companies in the French Life Sciences industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 27% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the French Healthcare industry?
| FR Market | 0.042% | |
| Healthcare | 6.14% | |
| Life Sciences | 15.40% | |
| Clinical Research and Equipment | 15.40% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DIM Sartorius Stedim Biotech | €173.85 | 18.4% +€2.6b | -38.4% | PE99.8x | |
| ERF Eurofins Scientific | €53.64 | 10.9% +€940.5m | -13.9% | PE31.5x |